Efficient conversion of tetrapeptide-based TSAO prodrugs to the parent drug by dipeptidyl-peptidase IV (DPPIV/CD26)

Antiviral Research

Volumn 76, Issue 2, 2007, Pages 130-139

  García Aparicio, Carlos ^a   Diez Torrubia, Alberto ^a   Balzarini, Jan ^b   Lambeir, Anne Marie ^c   Velázquez, Sonsoles ^a   Camarasa, María José ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

CD 26; Dipepeptidyl peptidase IV (DPPIV); Prodrugs; TSAO conjugates; TSAO T compounds

Indexed keywords

ANTIVIRUS AGENT; DIPEPTIDYL PEPTIDASE IV; LYSYLPROLYLASPARTYLPROLINE; N 3 AMINOPROPYL TERT BUTYL DIMETHYLSILYLSPIROAMINOOXATHIOLE DIOXIDE; PRODRUG; TETRAPEPTIDE; UNCLASSIFIED DRUG; VALYLALANYLVALYLALANINE; VALYLALANYLVALYLPROLINE; VALYLPROLYLVALYLPROLINE;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CHEMICAL REACTION; DRUG CONJUGATION; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME PURIFICATION; PRIORITY JOURNAL; REACTION ANALYSIS; SERUM;

ANTIGENS, CD26; CELL LINE; HIV-1; HUMANS; OLIGOPEPTIDES; PRODRUGS; SERUM; SOLUBILITY; SPIRO COMPOUNDS; THYMIDINE;

BOVINAE;

EID: 34548605428     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.06.009     Document Type: Article

References (17)

1. Augustyns K., Bal G., Tonus G., Belyaev A., Zhang X.M., Bollaert W., Lambeir A.M., Dunix C., Goossens F., and Haemers A. The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr. Med. Chem. 6 (1999) 311-327
2. Balzarini J., Pérez-Pérez M.-J., San-Félix A., Schols D., Perno C.F., Vandamme A.-M., Camarasa M.-J., and De Clercq E. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4392-4396
3. Balzarini J., Naesens L., Bohman C., Pérez-Pérez M.-J., San-Félix A., Camarasa M.-J., and De Clercq E. Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]3-N-methyl-thymine]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide). Biochem. Pharmacol. 46 (1993) 69-77
4. Balzarini J., Andersson E., Schols D., Proost P., Van Damme J., Svennerholm B., Horal P., and Vahlne A. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH2). Int. J. Biochem. Cell Biol. 36 (2004) 1848-1859
5. Bonache M.C., Chamorro C., Velázquez S., De Clercq E., Balzarini J., Rodríguez Barrios F., Gago F., Camarasa M.-J., and San-Félix A. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J. Med. Chem. 48 (2005) 6653-6660
6. Camarasa M.-J., Pérez-Pérez M.-J., San-Félix A., Balzarini J., and De Clercq E. 3′-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″,2″-dioxide]pyrimidine nucleosides. J. Med. Chem. 35 (1992) 2721-2727
7. Camarasa M.-J., San-Félix A., Velázquez S., Pérez-Pérez M.-J., Gago F., and Balzarini J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr. Top. Med. Chem. 4 (2004) 945-963
8. De Castro S., Lobatón E., Pérez-Pérez M.-J., San-Félix A., Cordeiro A., Andrei G., Snoeck R., De Clercq E., Balzarini J., Camarasa M.-J., and Velázquez S. Novel [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity. J. Med. Chem. 48 (2005) 1158-1168
9. De Meester I., Vanhoof G., Lambeir A.-M., and Scharpé S. Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5). J. Immunol. Meth. 189 (1996) 99-105
10. De Meester I., Korom S., Van Damme J., and Scharpe S. CD26, let it cut or cut it down. Immunol. Today 20 (1999) 367-375
11. De Meester I., Lambeir A.-M., Proost P., and Scharpe S. Dipeptidyl peptidase IV substrates-an update on in vitro peptide hydrolysis by human DPPIV. Adv. Exp. Med. Biol. 524 (2003) 3-17
12. García-Aparicio C., Bonache M.-C., De Meester I., San-Félix A., Balzarini J., Camarasa M.-J., and Velázquez S. Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach. J. Med. Chem. 49 (2006) 5339-5351
13. Lambeir A.-M., Durinx C., Scharpe S., and De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40 (2003) 209-294
14. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85 (1999) 9-24
15. Mentlein R. Cell-surface peptidases. Int. Rev. Cytol. 235 (2004) 165-202
16. Vanhoof G., Goossens I., De Meester I., Hendriks D., and Scharpé S. Proline motifs in peptides and their biological processing. FASEB J. 9 (1995) 736-744
17. Yaron A., and Naider F. Proline-dependent structural and biological properties of peptides and proteins. Crit. Rev. Biochem. Mol. Biol. 28 (1993) 31-81